STOCK TITAN

Elanco Animal Health Incorporated - ELAN STOCK NEWS

Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:

  • Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
  • Helping pets live longer, healthier lives through advanced veterinary products.
  • Improving food safety standards globally.

Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.

Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.

Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.

Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.

Rhea-AI Summary

Elanco Animal Health reported Q3 2022 results with revenues of $1,028 million, a 9% decline from last year. Despite challenges, adjusted EPS rose 5% to $0.20. A net loss of $49 million was recorded, improving from $104 million in Q3 2021. The company updated its full-year guidance, forecasting revenue between $4,385 million and $4,430 million. Significant foreign exchange impacts are anticipated, with a loss of around $225 million. Elanco expects five blockbuster product approvals by mid-2024, including a parasiticide and a monoclonal antibody for canine parvovirus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health Incorporated (NYSE: ELAN) will publish its third quarter 2022 financial results on November 8, 2022. Following this, a conference call with investors and media is scheduled for 8:00 a.m. ET to discuss the company’s performance in detail. Participants can access the live webcast through the company's investor relations website. Elanco aims to innovate and deliver products for animal health, enhancing the welfare of animals and providing value across the animal health ecosystem.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) announced that Scott Ferguson is stepping down from its Board of Directors to focus on other commitments with Sachem Head Capital Management. Ferguson expressed confidence in Elanco's strategy, emphasizing its path to creating shareholder value through cost discipline and innovation. R. David Hoover, chairman of the board, acknowledged Ferguson's contributions during his tenure since December 2020. Jeffrey N. Simmons, CEO, reaffirmed strong strategy execution, promising upcoming innovations that aim to enhance value for customers and shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.07%
Tags
management
Rhea-AI Summary

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. Jeff Simmons, the president and CEO, is scheduled for a fireside chat at 2:50 p.m. Eastern time.

A live audio webcast of the event will be accessible via the company’s investor website, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
-
Rhea-AI Summary

Elanco Animal Health has released its 2021 Environmental, Social and Governance (ESG) Report detailing advances in sustainability and health initiatives. The report highlights efforts in workforce diversity with goals to increase women's leadership representation to 42% by 2023, and People of Color to 20%. Environmental impact is addressed by reducing emissions by 8% since 2020 and transitioning to renewable energy. Elanco also launched a global Animal Welfare Policy and improved access to veterinary care for 20 million farm animals in East Africa.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health reported a Q2 2022 revenue of $1,177 million, an 8% decrease year-over-year. The company’s net loss was $22 million, an improvement from $210 million last year. Adjusted net income reached $177 million with an adjusted EPS of $0.36. Full-year revenue guidance is now $4,465 to $4,550 million. Adjusted EBITDA for Q2 was $300 million, with margins improving to 25.5%. Amid macroeconomic challenges, Elanco emphasizes its strong pipeline, including new products set for market launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
Rhea-AI Summary

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2022 financial results on Monday, August 8, 2022. A conference call will take place at 8:00 a.m. eastern time for detailed discussion of its performance. Investors and media can access a live webcast from Elanco's website, with a replay available shortly after the call. Elanco is committed to innovating animal health products and services, enhancing animal health, and delivering value to stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health has launched the "Unleash Joy" anthem and a music video featuring popular pets to promote their Seresto® collars, which offer eight months of flea and tick protection. The campaign emphasizes responsible pet ownership while encouraging pet owners to enjoy summer activities. Veterinarian David Gosche highlights the balance between fun and the risks of flea and tick-borne diseases during summer. Owners can share their pets' summer adventures on Instagram using the hashtag #SerestoJoinTheJoy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
none
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13-14, 2022. CFO Todd Young will be featured in a fireside chat on June 13 at 6:20 p.m. ET. Investors can access a live audio webcast via Elanco's investor website, with a replay available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
conferences

FAQ

What is the current stock price of Elanco Animal Health Incorporated (ELAN)?

The current stock price of Elanco Animal Health Incorporated (ELAN) is $12.05 as of December 26, 2024.

What is the market cap of Elanco Animal Health Incorporated (ELAN)?

The market cap of Elanco Animal Health Incorporated (ELAN) is approximately 5.8B.

What is Elanco Animal Health's core mission?

Elanco's core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue by enhancing food security, improving pet health, and elevating food safety standards globally.

In how many countries does Elanco operate?

Elanco operates in over 90 countries worldwide.

What recent collaborations has Elanco engaged in?

Elanco recently collaborated with Agtech company Cattler to provide data-driven solutions to cattle farmers through services like Benchmark™ and Experior™.

What is the significance of Elanco's partnership with Athian?

The partnership with Athian aims to create a livestock carbon insetting marketplace, reducing greenhouse gas emissions and promoting sustainable farming practices.

What are some of Elanco's notable products?

Elanco's notable products include Seresto®, Experior™, and Bovaer®, the latter being a methane-reducing feed ingredient for cattle.

How is Elanco addressing sustainability in animal farming?

Elanco addresses sustainability through innovative products like Bovaer®, which reduces methane emissions from cattle, and partnerships aimed at creating carbon insetting marketplaces.

What financial goals has Elanco set for 2024?

Elanco expects constant currency revenue growth of 2% to 3% for 2024, driven by new product launches and operational improvements. They also anticipate significant debt reduction through strategic divestitures.

How does Elanco contribute to food safety?

Elanco contributes to food safety by developing products that improve the health and performance of farm animals, thereby ensuring a safer and more reliable food supply.

What is Elanco's approach to innovation?

Elanco's approach to innovation involves continuous R&D investments, strategic partnerships, and the development of new products that address pressing issues in animal health and sustainability.

How does Elanco support the health and wellness of pets?

Elanco supports pet health through an extensive range of veterinary products designed to improve the quality and longevity of pets' lives.

Elanco Animal Health Incorporated

NYSE:ELAN

ELAN Rankings

ELAN Stock Data

5.85B
490.44M
0.71%
98.94%
3.07%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
GREENFIELD